{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001820","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.342978+00:00","generated_at":"2026-06-20T00:40:34.405493+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEXX Q4 revenue +7% organic; EPS $2.05; FY23 guidance rev $3.59B-$3.69B, EPS $9.27-$9.75","bullets":["Q4 revenue $829M (+3% reported, +7% organic); EPS $2.05 (+8% reported, +14% comparable).","FY2022 revenue $3,367M (+5% reported, +7% organic); EPS $8.03 (-7% reported, -1% comparable, including discrete R&D headwind).","CAG Diagnostics recurring revenue grew 4% reported, 8% organic in Q4; global premium instrument installed base up 13% YoY.","FY2023 guidance: revenue $3.59B-$3.69B (6.5%-9.5% reported growth); EPS $9.27-$9.75 (16%-21% reported growth).","Q4 operating margin 27.3% (+240bps reported); 2023 operating margin target 29.0%-29.6%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001820","json":"https://secwatch.observer/filing/0000950170-23-001820.json","markdown":"https://secwatch.observer/filing/0000950170-23-001820.md","text":"https://secwatch.observer/filing/0000950170-23-001820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000095017023001820/0000950170-23-001820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000095017023001820/idxx-20230206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:40:34.405493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b76589d5fad69f1712952f5b4787344c6bf32f70","claim":"IDEXX LABORATORIES INC /DE updated its the quarter and year ended December 31, 2022 guidance (initiated).","evidence_excerpt":"IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874716/000095017023001820/0000950170-23-001820-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}